SHTDY (Sinopharm Group Co) Quality Rank


SHTDY Sinopharm Group Co Ltd SHTDY
73 GF Score
Price $10.45
GF Value $13.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Sinopharm Group Co Quality Rank Related Terms

SHTDY
73GF Score
Sinopharm Group Co Ltd SHTDY
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sinopharm Group Co (SHTDY) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $10.45 is trading 19.9% below its estimated GF Value™ of $13.05. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDY:

  • Quality Rank:
  • GF Value™: $13.05 vs. price of $10.45 (19.9% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score

Get the complete analysis for SHTDY

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.45
Price
$13.05
GF Value